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Epithelial–mesenchymal transition (EMT) and cell transformation have been well-
documented in multiple cancer cell models and are believed to be one of the earliest
events in tumor progression. Genetic and epigenetic modifications shift cells toward either
end of the EMT spectrum, and can be influenced by the microenvironment surrounding
a tumor. EMT and mesenchymal–epithelial transition are critical to normal function and
development and an intricate network of transcription factors and transcriptional regula-
tors tightly regulates these processes. As evidenced in normal and transformed cell lines,
many signaling pathways trigger EMT during development and differentiation.The signaling
pathways include those triggered by different members of the transforming growth factor
superfamily, epidermal growth factor, fibroblast growth factor, hepatocyte growth factor,
hypoxia-inducible factor, Wnt, Notch, and many others. Functional redundancies allow cells
to undergo EMT even if these key transcriptional regulators are lacking, but these same
redundancies also make these pathways particularly susceptible to gain-of-function muta-
tions or constitutive signal activation; the “forced” transition toward either a mesenchymal
or epithelial phenotype.
Keywords: epithelial–mesenchymal transition, microenvironment, invasion, motility, transforming growth factor-
beta
INTRODUCTION
Historically, signaling pathways were studied in isolation and
treated as linear entities that never interacted; however, studies
in the emerging field of systems biology have provided a grow-
ing appreciation of the importance of pathway crosstalk and
emphasized the complexity of signaling webs during development
and tumor progression. This is especially true for the process
known as epithelial–mesenchymal transition (EMT). EMT was
first described in the 1980s because of its pivotal role during
embryonic development and was later implicated in the phys-
iological response to injury (1). EMT is critically involved in
normal embryogenesis and development and epithelial cells have
Abbreviations: bHLH, basic helix–loop–helix; BMP, bone morphogenetic protein;
CTBP, C-terminal binding protein; CTC, circulating tumor cell; CXCR4, C–X–C,
chemokine receptor 4; EGFR, epidermal growth factor receptor; EMT, epithelial–
mesenchymal transition; ERK, extracellular signal-regulated kinase; FGF, fibroblast
growth factor; GRB2, growth factor receptor-bound protein 2; GSK, glycogen syn-
thase kinase; HDAC, histone deacetylase; HGF, hepatocyte growth factor; HIF,
hypoxia-inducible factor; IGF, insulin-like growth factor; IκB, nuclear factor of
kappa light polypeptide gene enhancer in B-cells inhibitor, alpha; IL-6 interleukin
6; IRAK, interleukin-1 receptor-associated kinase; JNK, c-Jun N-terminal kinase;
MAPK, mitogen-activated protein kinase; MET, mesenchymal–epithelial transition;
MMP3, matrix metalloproteinase-3; MMSET, multiple myeloma SET domain; NF-
κB, nuclear factor kappa-light-chain-enhancer of activated B-cells; PDGF, platelet-
derived growth factor; PI3K, phosphatidylinositol-3-kinase; PTEN, phosphatase and
tensin homolog; PTHRP, parathyroid hormone-related protein; RANKL, receptor
activator of NF-κB ligand; SDF-1, stromal-derived-factor-1; SOS, son of sevenless;
TGF, transforming growth factor; TNF, tumor necrosis factor; TRAIL, tumor necro-
sis factor-related apoptosis-inducing ligand; TRAF, TNF receptor-associated factor;
ZEB, zinc-finger E-box-binding homeobox; ZO, zonula occludens.
developed an intricate network of signaling pathways that include
redundancies that safeguard and ensure proper functioning even
in the event of a genetic lesion. However, these functional redun-
dancies also leave the signaling network particularly susceptible
to gain-of-function mutations and inappropriate signal amplifi-
cation, eventually leading to tumor progression. Thus, EMT is not
only a key biological process during embryonic morphogenesis but
also a defining characteristic. EMT is also one of the earliest steps
of solid tumor progression, associated with tumor growth, inva-
sion, and metastasis, and contributes to the conversion of tumors
from low- to high-grade malignancy (2, 3).
During EMT, epithelial cells undergo a developmental switch
that results in decreased adhesion and loss of cell polarity,
increased proliferation, and increased motility and invasiveness
(4). Invasion is a key step to progression toward a malignant phe-
notype,and occurs when tumor cells translocate from the relatively
constrained initial neoplastic mass into neighboring host tissues.
To accomplish this, cancer cells must somehow detach from the
primary tumor and migrate through surrounding tissues, opening
up the opportunity to penetrate the basal-membrane surround-
ing a blood or lymphatic vessel, travel throughout the body via
the circulatory system, and colonize distant sites where metastatic
foci can be formed. Growing evidence suggests that in order for
benign cancer to progress toward malignant disease tumor cells
undergo EMT (5). The EMT process is associated with a num-
ber of morphological and biochemical changes where polarized
and basal-membrane anchored epithelial cells acquire a mesenchy-
mal, fibroblastoid phenotype. Morphologically, during the onset
of EMT cells transform from a cuboidal epithelial-like cell to a
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spindle-shaped mesenchymal-like cell. These changes are associ-
ated with the down-regulation of epithelial cell surface markers
and cytoskeleton components [e.g., E-cadherin, zonula occludens
(ZO)-1, claudins, occludins, cytokeratins] and the up-regulation
of mesenchymal markers (e.g., vimentin and α-smooth muscle
actin) and extracellular matrix components (e.g., collagens and
fibronectin) (6). The essential features of EMT as it relates to
tumor progression are disruption of intercellular contacts and
enhanced migration, the capability of matrix remodeling and
tumor tissue remodeling, invasion into and migration through
the extracellular matrix without the assistance of cell–cell con-
tacts, and apoptotic resistance. Although the molecular basis of
EMT have not been completely elucidated, in vitro and in vivo
model systems have identified five main interconnected trans-
duction pathways that lead to EMT and EMT-like phenotypes,
many of which connect EMT to the extracellular matrix and the
microenvironment surrounding tumors: tyrosine kinase receptors
including the receptors for platelet-derived growth factor (PDGF),
epidermal growth factor (EGF), insulin-like growth factor (IGF),
hepatocyte growth factor (HGF), and fibroblast growth factor
(FGF); nuclear factor kappa-light-chain-enhancer of activated B-
cells (NF-κB); integrins; transforming growth factor (TGF)-β;
Wnt; and many others (7). Many of these pathways share com-
mon downstream signaling effectors, highlighting the complexity
of the signaling networks involved in EMT (8). In this review,
we summarize some of the most prominent EMT-inducing net-
works and the associated molecular events leading to the tran-
sition of differentiated, polarized epithelial cells to a fibroblastic,
mesenchymal cell.
EMT-RELATED SIGNALING NETWORKS THAT REGULATE
E-CADHERIN
Most signaling pathways involved in the initiation of EMT result
in the down-regulation of E-cadherin, an epithelial cell adhesion
molecule that serves as a “master programmer” of EMT [recently
reviewed in Ref. (9)]. A critical mediator of EMT, E-cadherin has
often been described as the gatekeeper of EMT (10, 11) and in
most cell types, the loss of functional E-cadherin results in loss
of cell adhesion, leading to rapid cell growth and metastasis (9).
In addition to its role in cell adhesion, E-cadherin is involved in
transmitting signals within cells that control cell maturation, dif-
ferentiation, motility, and growth. E-cadherin also acts as a tumor
suppressor protein, preventing cells from growing and dividing too
rapidly or in an uncontrolled way; E-cadherin down-regulation
has been implicated in cell migration and invasion in murine mod-
els of mammary, prostate, and pancreatic cancer (12). Providing
further correlative support for a role of E-cadherin during tumor
formation, E-cadherin is inactivated in many diffuse-type cancers
such as lobular breast carcinoma and gastric carcinoma, in which
cells in a tumor mass lose epithelial characteristics and exhibit
a highly invasive EMT-derived histological pattern. E-cadherin
down-regulation occurs in solid, non-diffuse-type cancers at the
tumor-stroma boundary where single EMT-derived tumor cells
invade otherwise healthy tissue. In the case of single cell infil-
tration, E-cadherin loss and subsequent resulting EMT could be
a transient, reversible process, possibly regulated by the tumor
microenvironment; neoplastic cells that have undergone EMT
during invasion seem to regain E-cadherin expression and their
epithelial, cohesive characteristics at the secondary foci (13).
Molecular events during EMT result in transcriptional regula-
tion of the transcription factors Snail (Snail1), Slug (Snail2), zinc-
finger E-box-binding homeobox (ZEB)1/2, and Twist1/2, leading
to a molecular fingerprint that serves as a phenotypic marker dur-
ing EMT (14). In particular, Snail, Slug, Twist, SIP1/ZEB, and
E47 negatively regulate E-cadherin expression (14, 15) and dis-
play overlapping functional redundancy, in part through their
common recognition of E-box sequences (Figure 1). Snail and
Slug initiate EMT during development, fibrosis, and the initial
invasion of cancer by repressing epithelial genes like E-cadherin
by binding to E-box DNA sequences through their carboxy-
terminal zinc-finger domains (16). While ZEB1/2 also binds to
E-box sequences, ZEB-mediated transcriptional repression often
involves the recruitment of a C-terminal-binding protein (CTBP)
co-repressor (16). Twist1/2 belongs to the basic helix–loop–helix
(bHLH) family of transcription factors and represses E-cadherin
expression independently of Snail, probably through interactions
with co-repressors (16). E47 also binds to the E-cadherin E-box,
but appears to independently promote angiogenesis during tumor
growth (17). Involved in most physiological EMT situations, over-
expression of Snail, Slug, ZEB1/2, or Twist1/2 in epithelial cell
lines typically induces EMT (18–20). These transcription fac-
tors also regulate genes other than E-cadherin. Twist and Snail
have emerged as promising candidates of EMT “master genes”
because they regulate genes involved in motility, proliferation, dif-
ferentiation, and survival, including matrix metalloproteinases,
N-cadherin, and E-cadherin in in vitro and in vivo experiments
(19, 21). The signaling pathways involved in EMT should not
be viewed in isolation, for evidence of interactions and crosstalk
FIGURE 1 |Transcriptional regulators of EMT regulate E-cadherin.
Shown is a graphical representation of how several of transcriptional
regulators of EMT regulate E-cadherin expression. Arrows represent
up-regulation, T-bars represent inhibition.
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between multiple pathways exists. For example,Snail and Slug both
repress E-cadherin levels and are co-expressed in various carcino-
mas, including breast and ovarian cancer (22). Nevertheless, by
employing multiple signaling cascades, Snail and Slug could have
both overlapping and simultaneously distinct roles during tumor
progression, similar to what has been described for Dnmt3a/b and
Vav1/2 during hematopoiesis (22–25). β-Catenin not only inter-
acts with E-cadherin to maintain cell–cell adhesion but is also
shuttled to the nucleus where Wnt serves as the transcription effec-
tor of the Wnt signaling pathway to promote proliferation and cell
survival (26). This is particularly relevant during EMT because
Wnt gene mutations and aberrant activation of β-catenin are
considered critical events in tumor cell maintenance and growth
(27). Glycogen synthase kinase (GSK)-3β-mediated stabilization
of Snail is not only part of the Wnt signaling cascade but is also
required in colorectal cancer cells for EMT induced by the pro-
inflammatory cytokine tumor necrosis factor (TNF)-α (28). Slug
was identified as a downstream Wnt signaling pathway effector in
a basal-like carcinoma model that also linked the Wnt pathway
to tumor proliferation and self-renewal (29). These finding sug-
gest that Slug and Wnt play important roles in maintaining the
stemness of human mammary tumor cells.
EMT AND CIRCULATING CANCER CELLS
It is believed that some cells slough off the outer edges of a tumor
as it proliferates and are swept away by the bloodstream or lym-
phatic system (30). These rare so-called circulating tumor cells
(CTCs) from a primary tumor have the capacity to be shed into
the vasculature, where they circulate throughout the bloodstream
and eventually find a suitable location to colonize and form distant
metastases in new tissues (30). One of the key features of the CTC
theory of metastasis is that these cells are able to become quiescent
until microenvironmental conditions favor growth. Interestingly,
two EMT-inducers, Snail and Twist, are upregulated in CTCs and
allow cancer cell populations to revert to a stem-cell-like quies-
cent state (31). Further supporting a link between EMT and CTCs,
more than 80% of CTCs collected based on the expression of an
epithelial marker (EpCAM) also expressed a mixture of epithelial
and mesenchymal markers, suggesting that these CTC were cur-
rently transitioning along the EMT axis (32). Indeed, these cells
expressed many molecular markers only seen in cells undergoing
EMT, including epithelial proteins such as cytokeratin and E-
cadherin; mesenchymal proteins including vimentin, N-cadherin,
and O-cadherin; and the stem cell marker CD133 (32). Addition-
ally, CTC-like cells increased after immortalized human mammary
epithelial cells were transfected with Ras to initiate EMT (33, 34).
Further implicating EMT in CTC production,CTCs obtained from
metastatic breast cancer patients express a much higher rate of
Twist and vimentin, two markers of EMT, than patients with early
breast cancer (35). Many of the same microenvironmental cues
that regulate EMT also seem to be upregulated in CTCs, espe-
cially hypoxia and inflammatory mediators such as NFκB and
TGFβ (36). Inflammatory signaling mediators emanating from the
microenvironment also play a critical role in the maintenance of
CTCs. The receptor for stromal-derived-factor-1 (SDF-1), C–X–
C chemokine receptor 4 (CXCR4) enhances the survival of CTCs
as they circulate throughout the body (37). Microenvironmental
signals also serve as cues to tell CTCs to leave the circulation and
to colonize distant organs. In breast cancer, bone marrow cells
secrete parathyroid hormone-related protein (PTHRP), TNF-α,
interleukin 6 (IL-6), and/or IL-11 stimulate the release of the
receptor activator of NF-κB ligand (RANKL) from osteoblasts and
suppress the release of the RANKL antagonist osteoprotegerin,
allowing for breast tumor CTCs to colonize the bone marrow
(37). TNF-related apoptosis-inducing ligand (TRAIL) has also
been recently shown to contribute to EMT by miR-221-induced
suppression of phosphatase and tensin homolog (PTEN) (38).
Similarly, interactions between endothelial selectins and selectin
ligands expressed on CTCs, up-regulation of adhesion molecules,
and interactions between adherent neutrophils within inflamed
sinusoids and CTCs contribute metastatic colonization of the liver
(39). Together, these examples paint a complex picture of signaling
crosstalk that intersect at the CTC and play a critical role in tumor
progression.
MicroRNA REGULATION OF EMT
MicroRNAs (miRNAs) are small non-coding RNA molecules that
play key roles in the regulation of transcriptional and post-
transcriptional gene expression (40). In addition to their impor-
tant roles in healthy individuals, miRNAs are important players
during EMT and are differentially expressed in a broad range
of cancers (41). Because a single miRNA can target several mes-
senger RNAs, dysregulation of miRNAs can influence multiple
signaling pathways leading to tumor formation and metastasis.
For example, miR-138 controls EMT by targeting at least three
genes: vimentin, ZEB2, and enhancer of zeste homolog EZH2
(42). Similarly, the miR-200 micro RNA family targets at least two
transcriptional repressors of E-cadherin, ZEB1 and ZEB2; alter-
ing miR-200 in transformed cell lines induced changes consistent
with either inducing EMT or the reverse process, mesenchymal–
epithelial transition (MET) (43). Reduced expression of miR-30a
promotes TGF-β-induced EMT by targeting SNAI1 (44). In addi-
tion to the control of transcription factors, miRNA also affects
multiple aspects of the EMT process, including increased motil-
ity and invasiveness, cell adhesion, disassembly of epithelial cell
junctions, and destabilization of tight junctions (45).
GENETIC LESIONS AND EPIGENETIC MODIFICATIONS IN
EMT
Many signaling pathways associated with EMT result in increased
cellular proliferation and create feedback loops, resulting in a
perpetual proliferative state during the initial stages of EMT. In
normal, healthy cells, genomic integrity during cell division is
ensured by DNA repair and cell cycle checkpoints that respond
to DNA damage by inhibiting critical cell cycle events (46). How-
ever, the increased proliferation rate in cells undergoing EMT
provides tumor cells an opportunity to proceed through mito-
sis without high-fidelity proofreading and/or repair, consequently,
resulting in the potential of increased mutation rates (47). How-
ever, increased proliferation during EMT is not sufficient for
tumor development on its own and additional genetic lesions
are required to move past the initial cellular dysplasia toward a
malignant tumor. Consistent with this model, the carcinogenic
potential of estradiol, for example, is thought to be mediated
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by a combination of proliferation and increased mutation rate
[reviewed in Ref. (48, 49)].
Epigenetic deregulation of gene expression is involved in the
initiation and progression of multiple cancers and an important
initiator of EMT. Similar to its role in differentiation, develop-
ment, and malignant transformation, epigenetic reprograming
during EMT is largely mediated by chromatin remodeling (50).
DNA methylation patterns are preserved during EMT and sus-
tained EMT activation leads to epigenetic alterations, inducing
heritable changes that maintain the mesenchymal phenotype even
after EMT-initiating signals are removed. Epigenetic modifica-
tions, especially histone and DNA methylation, are critical to
gene regulation and establish patterns of gene repression during
development and EMT (51). Snail represses E-cadherin expres-
sion by forming a co-repressor complex with histone deacety-
lase HDAC1 and HDAC2, resulting in E-cadherin silencing and
in vivo pancreatic cancer progression (52). Overexpression of
the histone methyltransferase MMSET (multiple myeloma SET
domain) in prostate cancer influences histone 3 lysine 36 dimethy-
lation (H3K36me2) and lysine 27 tri-methylation (H3K27me3).
MMSET overexpression in immortalized prostatic epithelial cells
leads to increased migration, increased invasion, morphological
changes, and altered gene expression consistent with transition
from an epithelial cell-like state to a mesenchymal cell-like state
(53). Mediated by the ability of MMSET-mediated activation of
TWIST1, a gene implicated in tumor-associated EMT and inva-
sion (19), these data suggest that deregulated MMSET results in
aberrant epigenetic gene regulation, leading to tumor progres-
sion and metastasis. Genome-wide histone maps focusing on H3
lysine 4 and lysine 27 tri-methylation (H3K4me3 and H3K27me3)
identified differentially expressed genes in embryonic stem cells
(54–57), hematopoietic stem cells/progenitor cells (58), T cells
(59), and in prostate cancer cells (60). Although DNA methyla-
tion has been implicated in the transition from EMT to MET,
reversible histone modifications are the predominant factors in
reactivation of E-cadherin expression during the transition from
EMT to MET (61).
Genome-scale mapping revealed that most chromatin changes
are heterochromatin K9-modifications, suggesting that EMT is
characterized by the epigenetic reprograming of specific, large
chromatin domains across the genome (50). Similarly, clustered
chromatin profiles using combinatorial patterns of posttransla-
tional histone modifications and covalent changes to genomic
DNA discovered a distinct chromatin signature among genes in
well-established EMT pathways including the epidermal growth
factor receptor (EGFR), suggesting that chromatin remodeling
of EGFR plays an important role in EMT (62). Acetylation,
regulated mainly through HDACs also affects EGFR expres-
sion and downstream signaling. HDAC6 up-regulation slows
EGFR endocytic trafficking from early endosomes to late endo-
somes in renal epithelial cells and HDAC6 inhibition results
in decreased phosphorylation of extracellular signal-regulated
kinase (ERK) 1/2, a downstream target of EGFR (63). Future
experiments should determine if these findings are common to
EMT and determine if similar epigenetic reprograming occurs
in other physiological contexts. Aside from this role in epi-
genetic reprograming, crosstalk between the more traditionally
known EGFR signaling cascade and components of other sig-
naling pathways frequently leads to abnormal activation of pro-
proliferative and anti-apoptotic pathways. The most common
signaling cascades activated by EGFR are the phosphatidylinositol-
3-kinase (PI3K)/Akt, Ras/Raf/Mek/extracellular signal-regulated
kinase, and the Jak/Stat pathways (64) that both contribute to
the development of malignancies by impacting cell cycle progres-
sion, inhibition of apoptosis, angiogenesis, tumor cell motility,
and metastases (65). Crosstalk between EGFR and other signal-
ing pathways impact cancer treatment as well as the initiation of
EMT. For example,one well-known mechanism of resistance to the
selective EGFR inhibitor gefitinib/erlotinib is HGF receptor tyro-
sine kinase gene amplification. HGF receptor tyrosine kinase gene
amplification bypasses normal EGFR signaling to instead activate
AKT through HER3-mediated activation of PI3K in the presence
of EGFR tyrosine kinase inhibitors (66).
CROSSTALK BETWEEN TGFβ AND OTHER SIGNALING
PATHWAYS MEDIATING EMT
Signaling pathways are not independent from each other, but
rather interact to form complex signaling networks; the TGFβ
signaling pathway is no exception. Most likely, due to its involve-
ment during many cellular processes including proliferation, dif-
ferentiation, apoptosis, and cellular homeostasis, the TGFβ path-
way interacts with many other signaling pathways during EMT
(Figure 2). One mechanism by which TGFβ initiates EMT is by
removing β-catenin from adherens junctions in a process that
involves TGFβ-dependent PTEN dissociation from β-catenin and
Akt activation (67). Depending on the context, Notch can either
synergize with TGFβ/bone morphogenetic protein (BMP) signals
to induce target genes or inhibit TGFβ/BMP signaling (68–71). In
FIGURE 2 | Crosstalk between EMT-inducing signaling pathways.
Representation of some of the points of intersection between various
EMT-inducing signaling pathways. For clarity, branches that did not result in
crosstalk are not shown. Arrows represent up-regulation.
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the presence of other growth factors, TGFβ/BMP signaling gener-
ally stimulates migration and blocks endothelial cell proliferation,
but Notch signaling inhibits the migratory affect of BMP (72).
Stimulation of endothelial cells with BMP alone promoted cell
migration, but in the presence of Notch signaling, cell migra-
tion was inhibited (72). Interestingly, the dominance of Notch
signaling over BMP signaling was cell–cell contact-dependent, sug-
gesting that endothelial cells not in contact with surrounding cells
are stimulated by TGFβ to migrate until new cell–cell contacts
are established, at which point Notch induces gene expression
changes and arrests further migration (72). Similarly, Notch sig-
naling is necessary for growth arrest by TGFβ in epithelium; over
30% of TGFβ-induced epithelial genes require Notch signaling
for full expression (68). TGFβ leads to increased jagged-1 expres-
sion and siRNA-mediated knockdown of jagged-1 leads to reduced
TGFβ-induced p21 expression, rescuing TGFβ-inhibited prolifer-
ation (68). Therefore, TGFβ induces both c-myc, which stimulates
cell cycle progression, and jagged-1, which blocks cell cycle pro-
gression through stimulation of Notch and induction of p21.
Jagged-1 induction is rapid and transient, so a balance between
TGFβ/Notch-induced p21 and TGFβ/Smad-induced c-myc may
act as a switch to regulate cell proliferation (72).
Further supporting the importance of crosstalk during EMT,
Erk, c-Jun N-terminal kinase (JNK), and p38 indirectly regulate
TGFβ signaling, but TGFβ treatment leads to activation of Erk1/2
and mitogen-activated protein kinase (MAPK) signaling (73).
Smad-dependent signaling and MAPK-mediated Erk1/2 activa-
tion is believed to result in cross-talk between the TGFβ and EGF
signaling pathways (74). The MAPK/Erk signaling pathway also
mediates Smad2/3 phosphorylation and nuclear exclusion, which
is believed to be important for the attenuation of TGFβ-induced
nuclear translocation of MAPK (74). MAPK signaling also results
in Smad1/5 phosphorylation, leading to an inability to translo-
cate specific Smads into the nucleus (74). Erk-mediated Smad1
phosphorylation creates a docking site for the Smad1/5-specific E3
ubiquitin ligase, Smurf1. Smurf1 binding results in Smad ubiqui-
tination and eventual degradation and blocks Smad interactions
with the nuclear pore complex. MAPKs also regulate the pro-
tein stability of Smad4 and the inhibitory Smad7 (74), suggesting
that Smad3 is indispensable to the mediation of the pro-apoptotic
effects of TGFβ, Smad3, but not the closely related Smad2, is the
primary target of PI3K/Akt-mediated inhibition (74). In addition,
TGFβ regulates Akt activity and phosphatase and tensin homolog
(PTEN) function during EMT initiation. In addition to activating
the MAPK and PI3K/Akt pathways, ErbB signaling interacts with
TGFβ/Smad during development and breast cancer progression
(75). The PI3K/Akt pathway is also subjected to TGFβ regulation.
Akt activity increases in response to TGFβ treatment, which seems
to be required for a variety of TGFβ-induced activities, such as cell
migration of HER2-expressing breast cancer cells, EMT of nor-
mal mammary epithelial cells, cell survival of mouse hippocampal
neurons and mesenchymal cells, as well as growth stimulation of
certain fibroblasts (74, 75). EGFR and IL-6R signaling cross-talk
through JAK2/STAT3 to mediate EMT in ovarian carcinomas; acti-
vated STAT3 in high-grade ovarian carcinomas may occur directly
through activation of EGFR/IL-6R or indirectly through induc-
tion of IL-6R signaling (76). Another ligand of EGFR, TNF-α,
also induces EMT through NF-κB-mediated transcriptional up-
regulation of Twist1 (77). In breast cancer-related EMT, HER2/Ras
antagonizes TGFβ-induced apoptosis and cell cycle arrest while
simultaneously enhancing the pro-migratory and pro-invasive
functions of TGFβ (78). TGFβ transcriptionally downregulates
PTEN in Smad4 null pancreatic cancer cells and relies on the func-
tion of the Ras/MAPK pathway (73–75). EMT-related crosstalk is
also clinically relevant; pharmacological blockade of IGF-1R fully
prevented TGFβ’s ability to activate an EMT protein signature (79).
INVOLVEMENT OF THE MICROENVIRONMENT DURING EMT
The tumor microenvironment plays a crucial role in tumor pro-
gression and metastasis, and as tumors develop, the integrity
of the surrounding basement membrane plays a critical role in
invasion and metastasis. The tumor microenvironment is com-
posed of inflammatory and immune cells, physical interactions
with neighboring cells, oxygen and nutritional gradients, stromal
extracellular matrix, and soluble factors. Cells neighboring the
developing tumor secrete growth factors and inhibitory molecules
that regulate tumor proliferation and apoptosis, while tumor cells
simultaneously secrete factors to neighboring cells that regulate
adhesion. The temporal–spatial changes within the microenvi-
ronment surrounding tumors and the interaction between tumor
cells and their microenvironment are crucial to tumor initiation
and development, and are especially critical to cancer cell quies-
cence, tumor progression, invasion, tumor metastasis, and drug
resistance (Figure 3) (80).
FIGURE 3 | ECM/growth factor involvement in EMT. Shown are several
molecular mechanisms by which the cells within the tumor
microenvironment can influence tumor progression and EMT initiation.
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Many signals received from the tumor microenvironment can
initiate EMT including TGFβ, hypoxia-inducible factor (HIF)-1α,
EGF, WNTs, and Notch (21). Various signals trigger expression
of these transcription factors including heterotypic interactions
with neighboring cancer cells and interactions with adjacent
tumor-associated stromal cells. Epithelial–mesenchymal inter-
actions within the tumor microenvironment integrate several
important signaling molecules that are critical for tumor growth
and metastasis, including integrins, cytokines, and growth fac-
tors (81). Crosstalk between the TGFβ and HER2/Ras/MAPK
signaling pathways often leads to secretion of additional growth
factors and cytokines, including TGFβ itself, which in turn
promotes EMT and cell invasion, whereas JNK kinases neg-
atively regulate the autocrine expression of TGFβ1 (73, 75).
ErbB receptors and their ligands are also involved in cross-talk
between cancer cells and the tumor microenvironment. EGFR
is activated in tumor-associated endothelial cells, but not in
endothelial cells within uninvolved organ regions, suggesting that
EGFR activation and expression is partially determined by the
tumor microenvironment (82). As time goes on, the impor-
tance of the microenvironment to pathogenesis is becoming
clearer, from the role the ECM and matrix rigidity plays in
determining polarity, to the extracellular metabolism of growth
factors and matrix molecules during cancer progression and
metastasis.
Extracellular matrix proteins and physical properties within
the microenvironment can lead to tumor progression by activat-
ing EMT-inducing pathways within tumors. One key extracellular
matrix protein is matrix metalloproteinase-3 (MMP3), a matrix-
degrading enzyme secreted by stromal fibroblasts known to induce
in vitro and in vivo EMT in mammary epithelial cells (83). When
tumor cells are exposed to MMP3, transcription of a splice vari-
ant of Rac1 called Rac1b increases stimulating the production
of reactive oxygen species and expression of Snail1 (84). EGFR
activation in human carcinoma cell lines increases MMP-9 activ-
ity and is associated with increased in vitro cell invasion (85).
Synthetic low-molecular weight or endogenous MMP inhibitors
or an anti-catalytic MMP-9 antibody blocked increased invasive
activity after EGF-mediated induction, indicating EGFR activa-
tion results in enhanced MMP-9 expression and may facilitate
the removal of extracellular matrix barriers to tumor invasion.
Additional proteins within the basement membrane influence
EMT induction from ectopic exposure of MMP3. For exam-
ple, the laminin suppresses EMT in MMP3-treated cells, while
fibronectin promotes EMT due to interactions with specific inte-
grin receptors (7). During this process, α6-integrin sequesters
Rac1b from the basement membrane and is required for inhibition
of EMT by laminin; α5-integrin maintains Rac1b at the mem-
brane and is required for the promotion of EMT by fibronectin
(7). Additionally, matrix rigidity may also play an important
role during EMT. The microenvironmental stiffness surround-
ing cells impacts differentiation and response to external mol-
ecular cues, while epithelial cells treated with MMP3 undergo
EMT when cultured on plastic or glass, cells cultured on soft
matrices do not undergo EMT in response to treatment with
MMP3 (7).
INVOLVEMENT OF INFLAMMATORY SIGNALING IN EMT
The microenvironment surrounding a tumor is often dominated
by inflammatory cytokines that promote tumor initiation by
leading to increased angiogenesis, tumor growth, and tumor
progression (86). Tumor-associated macrophages secrete EGF to
neighboring cancer cells, which in turn stimulate macrophages to
facilitate intravasation and metastatic dissemination of the can-
cer cells (87, 88). Together, these findings substantiate a role of
EGF-mediated signaling not only in EMT and proliferative sig-
naling itself but also in the cross-talk between tumor cells and
the microenvironment. The tumor microenvironment is largely
orchestrated by inflammatory cells, which facilitate extracellu-
lar matrix breakdown, angiogenesis, and tissue remodeling, thus,
promoting tumor cell motility (89). Inflammatory cells play a
major role in secreting activating factors that lead to NF-κB acti-
vation; NF-κB is a key regulator of the inflammatory response
shown to regulate Slug and Snail (90). TGF-β activity is deregu-
lated during malignant cancer progression, and plays an important
role in EMT (91). Similarly, both TNFα and interleukin-1β (IL-
1β) are expressed at low levels in normal breast epithelial cells,
but are upregulated in the majority of breast cancer patients,
with pronounced expression of both cytokines in over 80% of
patients who experience breast tumor relapse (92). In vivo murine
breast models suggest increased expression and activity of TNFα
results in many cancer-promoting functions and that inhibition
of TNFα expression leads to reduced breast cancer malignancy
(93). Chronic TNFα expression in the tumor microenvironment
is correlated with a more aggressive tumor phenotype (93). IL-1β
upregulates a variety of processes that contribute to higher angio-
genesis, tumor growth, and tumor progression and is considered
a strong and causative pro-inflammatory factor whose expres-
sion is associated with advanced cancer (94). TNFα impacts cell
morphology and may cooperate with TGFβ to lead to EMT in non-
transformed breast epithelial cells (95). Sustained co-expression of
TNFα and IL-1β acts through the complex regulatory processes of
the EMT activators Zeb1, Snail, and Twist to result in morphologic
changes including cell spreading, protrusion formation, decreased
E-cadherin expression, and increased expression of vimentin, all
consistent with EMT (96).
HYPOXIA AND EMT
When microenvironmental cues are favorable for growth, rapid
cell growth with a tumor results in local hypoxia and nutrient
deficits, regardless of the oxygen tension surrounding the tumor
(97). Therefore, sustained tumor growth requires increased local
vasculature to provide oxygen and metabolites to feed the grow-
ing tumor (98) and the nutritionally impoverished and hypoxic
environment within tumors results in local changes in hypoxia-
related gene expression, contributing to tumor heterogeneity (99).
Tumor cells adjust to hypoxia and lack of nutrients not only
by activating specific pathways associated with angiogenesis but
also associated with hypermetabolism, glycolysis, and resistance
to acidosis-induced toxicity (100). Hypoxia genes, especially HIF-
1α, are frequently upregulated within many solid tumors and
promote tumor progression (101, 102). HIF-1α induces EMT
and self-renewal of cancer stem cells, and facilitates metastasis;
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knockdown of HIF-1α inhibits or even reverses the EMT-like phe-
notype (103, 104). Hypoxia-induced EMT is mediated by HIF-1α
via up-regulation of transcription effectors such as Snail, Twist,
and ZEB1/2 and results in the suppression of E-cadherin expres-
sion (105–107). Several additional signaling pathways that are
critical for embryonic development including Notch, Wnt, and
TGFβ are also involved in hypoxia-induced EMT. Demonstrating
a complex integration of hypoxic signals into EMT, Notch signal-
ing directly upregulates Snail, and potentiates HIF-1α recruitment
to the lysyl oxidase promoter, resulting in stabilization of Snail,
increased cell motility, and increased invasiveness (108). Simi-
larly, Wnt/β-catenin signaling enhances hypoxia-induced EMT
by increasing the EMT-associated activity of HIF-1α and pre-
venting cell death (109). Hypoxia also inhibits Wnt signaling
by interfering with β-catenin acetylation (110), blocking secre-
tion of Wnt (111), and activating Siah-1 in a p53-dependent
manner (112).
Depending on cell type, Wnt/β-catenin signaling also enhances
hypoxia-induced EMT by increasing the EMT-associated activity
of HIF-1α and preventing tumor cell death (109). HIF-1α also
competes with T-cell factor-4 (TCF-4) to bind β-catenin and form
a HIF-1α/β-catenin complex, accompanied by increased HIF-1α
transcriptional activity in colorectal tumors (113). TGFβ signal-
ing also integrates hypoxia-related cues, for TGFβ/Smad3 inhibit
vascular smooth muscle cell apoptosis through an autocrine sig-
naling mechanism involving VEGF (114). Adding further com-
plexity to the impact of TGFβ signaling, TGFβ not only activates
the Notch signaling pathway but Notch signaling also activates
TGFβ in rat mesangial cells under high-glucose conditions (68,
115). It is important to note that this example also highlights
how signals from the microenvironment can influence signaling
outcomes.
CONCLUSION
Epithelial–mesenchymal transition is a key physiological process
during normal development and regulated by an intricate network
of signaling pathways that allows for the integration of signaling
cues during embryonic morphogenesis. While these signaling net-
works allow for the precise control required for a major switch
from a differentiated epithelial cell into mesenchymal cell, it also
opens up the possibility of deregulation on multiple levels dur-
ing pathological processes such as cancer and fibrosis. Owing
to the complex interactions between these signaling pathways,
activating mutations in signaling molecules can be amplified.
Many of these potentially deregulated pathways converge on a
few master regulatory molecules or parallel pathways can induce
changes on various levels. Thus, it is plausible that EMT con-
tributes to cancer progression in various ways, including tumor
growth, invasion, and metastasis. Moreover, depending on the
nature of the genetic lesions, EMT can become a very individual-
ized process, adding to the complexity of cancer,while also opening
up the possibility of personalized medicine. Thus, our improved
understanding of EMT signaling networks and their association
with therapeutic resistance is imperative for future development
of novel anti-tumor drug and treatment strategies, especially in
high-grade tumors and tumors that have developed therapeutic
resistance.
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